The Treatment Landscape in Thyroid Cancer: a Focus on Cabozantinib

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2015 Aug 29

PMID 26316818

Citations 13

Authors

Steven P Weitzman

Maria E Cabanillas

Affiliations

Soon will be listed here.

Abstract

Although patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Progress in understanding the molecular aberrations in thyroid cancer has led to a change in the management of these cases. Since 2011, four multikinase inhibitors (MKIs) have been approved by the US Food and Drug Administration for thyroid cancer - cabozantinib and vandetanib for medullary thyroid cancer and sorafenib and lenvatinib for differentiated thyroid cancer. This change in the treatment landscape has raised challenges for practitioners who may not be familiar with the use of MKIs or with the treatment and natural history of advanced thyroid cancer in general. This article reviews the epidemiology, molecular drivers, and initial treatment of patients with thyroid cancer and offers practical guidance to assist with the determination of when to appropriately start an MKI. As an example, cabozantinib and its efficacy are discussed in detail. Close monitoring is required for all patients on targeted agents to assess for adverse effects and response to therapy. An approach to managing drug-related adverse events is detailed. Since these drugs are not curative and have not yet proven to prolong overall survival, it is critical to weigh the risks and benefits of treatment at every visit. The potential value of changing to a different agent following failure of an MKI is also addressed.

Citing Articles

Decoding kinase-adverse event associations for small molecule kinase inhibitors.

Gong X, Hu M, Liu J, Kim G, Xu J, McKee A Nat Commun. 2022; 13(1):4349.

PMID: 35896580 PMC: 9329312. DOI: 10.1038/s41467-022-32033-5.

Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis.

Bartz-Kurycki M, Oluwo O, Morris-Wiseman L Ther Adv Endocrinol Metab. 2021; 12:20420188211049611.

PMID: 34659736 PMC: 8511962. DOI: 10.1177/20420188211049611.

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.

Fullmer T, Cabanillas M, Zafereo M Front Endocrinol (Lausanne). 2021; 12:720723.

PMID: 34335481 PMC: 8321684. DOI: 10.3389/fendo.2021.720723.

Neoadjuvant selpercatinib for advanced medullary thyroid cancer.

Jozaghi Y, Zafereo M, Williams M, Gule-Monroe M, Wang J, Grubbs E Head Neck. 2020; 43(1):E7-E12.

PMID: 33169506 PMC: 7756223. DOI: 10.1002/hed.26527.

BPI-9016M, a c-Met inhibitor, suppresses tumor cell growth, migration and invasion of lung adenocarcinoma via miR203-DKK1.

Zhang P, Li S, Lv C, Si J, Xiong Y, Ding L Theranostics. 2019; 8(21):5890-5902.

PMID: 30613269 PMC: 6299440. DOI: 10.7150/thno.27667.

References

Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R . Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25(6):567-610. PMC: 4490627. DOI: 10.1089/thy.2014.0335. View

Kumar R, Knick V, Rudolph S, Johnson J, Crosby R, Crouthamel M . Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6(7):2012-21. DOI: 10.1158/1535-7163.MCT-07-0193. View

Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H . BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19):7099-109. DOI: 10.1158/0008-5472.CAN-04-1443. View

Nikiforova M, Nikiforov Y . Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2007; 8(1):83-95. DOI: 10.1586/14737159.8.1.83. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K . Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014; 2014:638747. PMC: 4177084. DOI: 10.1155/2014/638747. View

Tuttle R, Haddad R, Ball D, Byrd D, Dickson P, Duh Q . Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014; 12(12):1671-80. DOI: 10.6004/jnccn.2014.0169. View

Capp C, Wajner S, Siqueira D, Brasil B, Meurer L, Maia A . Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010; 20(8):863-71. DOI: 10.1089/thy.2009.0417. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

10.

Faivre S, Demetri G, Sargent W, Raymond E . Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007; 6(9):734-45. DOI: 10.1038/nrd2380. View

11.

Ruegemer J, Hay I, Bergstralh E, Ryan J, Offord K, Gorman C . Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988; 67(3):501-8. DOI: 10.1210/jcem-67-3-501. View

12.

Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P . Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011; 10(12):2298-308. DOI: 10.1158/1535-7163.MCT-11-0264. View

13.

Savvides P, Nagaiah G, Lavertu P, Fu P, Wright J, Chapman R . Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2012; 23(5):600-4. PMC: 3643255. DOI: 10.1089/thy.2012.0103. View

14.

Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L . Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384(9940):319-28. PMC: 4366116. DOI: 10.1016/S0140-6736(14)60421-9. View

15.

Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015; 372(7):621-30. DOI: 10.1056/NEJMoa1406470. View

16.

Haymart M, Banerjee M, Yin H, Worden F, Griggs J . Marginal treatment benefit in anaplastic thyroid cancer. Cancer. 2013; 119(17):3133-9. PMC: 4038063. DOI: 10.1002/cncr.28187. View

17.

Kim D, Jo Y, Jung H, Chung H, Song J, Park K . An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006; 91(10):4070-6. DOI: 10.1210/jc.2005-2845. View

18.

Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee A, Links T . Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007; 282(40):29230-40. DOI: 10.1074/jbc.M703461200. View

19.

Nguyen L, Holland J, Miles D, Engel C, Benrimoh N, OReilly T . Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015; 55(9):1012-23. DOI: 10.1002/jcph.510. View

20.

Fallahi P, Mazzi V, Vita R, Ferrari S, Materazzi G, Galleri D . New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci. 2015; 16(3):6153-82. PMC: 4394525. DOI: 10.3390/ijms16036153. View